This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Insulin lispro
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='96/969624/Cv/2'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='96/969624/Cv/2'> | ||
| - | Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. See also [https://en.wikipedia.org/wiki/Insulin_lispro]. | + | Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical [[insulin]] used to treat type 1 and type 2 diabetes. See also [https://en.wikipedia.org/wiki/Insulin_lispro]. Insulin lispro is a manufactured form of human insulin where the amino acids lysine and proline have been switched at the end of the B chain of the insulin molecule. This switch of amino acids mimics [[Insulin-like growth factor 1]] which also has lysine and proline in that order. |
<scene name='96/969624/Cv/3'>Insulin Lispro Analog</scene> ([[6nwv]]). | <scene name='96/969624/Cv/3'>Insulin Lispro Analog</scene> ([[6nwv]]). | ||
Current revision
| |||||||||||
